The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Continuing treatment with osimertinib can be a reasonable option (PMID 31882494)

Publications

Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D

Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.

Chest. 2022;162(5):1188-1198

Gou X, Yuan C, Bai Y, Shi L, Xing S, Ma H

Pneumonia caused by crizotinib: case report and review of literature.

Annals of palliative medicine. 2021;10(4):4932-4937

Kodama H, Wakuda K, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T

Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.

Investigational new drugs. 2021;39(2):571-577

Syunyaeva Z, Berghof K, Kauffmann-Guerrero D, Götschke J, Tufman A, Kahnert K

Late-onset severe pneumonitis under osimertinib.

AME case reports. 2019;3:39

Uchida T, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y, Hashimoto K, Nishihara F, Murayama Y, Kobayashi K, Kagamu H

Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer.

Thoracic cancer. 2019;10(4):975-979

Deng SM, Huang JA, Chen YB

Fatal interstitial lung disease associated with AZD9291.

Journal of cancer research and therapeutics. 2018;14(Supplement):S1227-S1229

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramali

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

The New England journal of medicine. 2018;378(2):113-125

Matsumoto Y, Kawaguchi T, Yamamoto N, Sawa K, Yoshimoto N, Suzumura T, Watanabe T, Mitsuoka S, Asai K, Kimura T, Yoshimura N, Kuwae Y, Hirata K

Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer.

Internal medicine (Tokyo, Japan). 2017;56(17):2325-2328

Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(12):1288-1296

Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, AURA3 Investigators

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

The New England journal of medicine. 2017;376(7):629-640

Ahn MJ, Sun JM, Lee SH, Ahn JS, Park K

Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(12):2051-2052

Noonan SA, Sachs PB, Camidge DR

Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(12):2253-2258

Mamesaya N, Kenmotsu H, Katsumata M, Nakajima T, Endo M, Takahashi T

Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody.

Investigational new drugs. 2017;35(1):105-107

Nie KK, Zou X, Geng CX, Zhang L, Liu SC, Zhang CL, Ji YX

AZD9291-induced Acute Interstitial Lung Disease.

Chinese medical journal. 2016;129(12):1507-8